A Bioequivalence study of a randomized, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Dapagliflozin/Metformin 10/500 mg tablets relative to XIGDUO XR (TABLETS 10 MG/500 MG) in healthy Thai participants under fed condition

Start Date09 Feb 2027

Sponsor / Collaborator-

ACTRN12626001133325

/ Not yet recruitingNot ApplicableIIT

The Evaluation of Two Response Thresholds to Continuous Ketone Monitoring Information Minimising Ketosis in young People with Type 1 Diabetes Treated with Dapagliflozin

Start Date11 Jan 2027

Sponsor / Collaborator-

KCT0012776

/ Not yet recruitingPhase 4IIT

Dapagliflozin in Patients with Non-Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (DAPA-HCM)

Start Date02 Jan 2027

Sponsor / Collaborator

Yonsei University Severance Hospital

100 Clinical Results associated with Dapagliflozin

100 Translational Medicine associated with Dapagliflozin

100 Patents (Medical) associated with Dapagliflozin

4,616

Literatures (Medical) associated with Dapagliflozin

01 Feb 2027·TISSUE & CELL

Dapagliflozin uncouples the anti-inflammatory and lipogenic effects of pioglitazone in valproic acid-induced steatohepatitis in rats: Lipid-sensing nuclear receptors (LXRα and PPARγ) as the molecular nexus between hepatoprotection and lipogenesis

Article

Author: Hassan, Hend M ; Elshenawy, Dina S ; Elkatary, Rania G ; Hammad, Maha O ; Saad, Somaya

Valproic acid (VPA) is a foundation antiepileptic medication, implicated in dose-dependent hepatotoxicity via mitochondrial dysfunction, progression of oxidative-inflammatory cascade, and steatosis. LXRα/PPARγ are crucial regulators of hepatic lipogenesis, representing a pertinent therapeutic target. Dapagliflozin, a SGLT2 inhibitor and pioglitazone, a PPARγ agonist, are emerging therapies for metabolic hepatic steatosis; however, while pioglitazone confers notable anti-inflammatory benefits, its hepatic PPARγ signaling remains a recognized concern. The current study targets the individual or combined modulatory effects of both drugs on the hepatic LXRα and PPARγ pathways in VPA-induced steatohepatitis in rats. Forty male Sprague-Dawley rats were randomized into five groups: Control, VPA (500 mg/kg/d given orally), PIO + VPA (10 mg/kg/d pioglitazone), DAPA + VPA (1 mg/kg/d dapagliflozin), and COMB (1 mg/kg/d dapagliflozin and 10 mg/kg/d pioglitazone). All prophylactic treatments were orally given 1 h prior to VPA. Spectrophotometry, RT-PCR, histopathological and immunohistochemical parameters were used to assess hepatic injury across groups. The results indicated that hepatocytes are nudged toward increased lipogenesis in the VPA group via activation of hepatic PPARγ (P < 0.001), LXRα (P < 0.01), SREBP1c (P < 0.001), and perilipin 2 (P < 0.05). VPA was associated with impaired LFTs, dyslipidemia, altered MDA/GSH equilibrium, and intense NF-κB immunoreactivity (all P < 0.001), besides significant fibrosis (P < 0.001) and elevated histopathology scores (P < 0.01). Relative to VPA, PIO + VPA exhibited significant hepatic anti-inflammatory and antioxidative benefits, restoring LFTs (P < 0.001) and MDA/GSH equilibrium (P < 0.001), alongside inhibiting NF-κB immunoreactivity (P < 0.001), however; it failed to significantly improve histopathological scores or lipogenic effectors (P > 0.05). Relative to VPA, DAPA + VPA and COMB groups showed a downregulation of hepatic lipogenic effectors (PPARγ at P < 0.001, LXRα at P < 0.01, SREBP1c at P < 0.001, and perilipin 2 at P < 0.05), with additional improvement of histopathological scores (P < 0.05), fibrosis (P < 0.001), and lipid profiles (P < 0.001) while simultaneously restoring LFTs and hepatic redox status (P < 0.001). Within the scope of the available literature, this study is the first to elucidate the divergent effects of pioglitazone and dapagliflozin on VPA-induced steatosis through the intricate hepatic LXRα/PPARγ signaling, underscoring the pronounced hepatoprotective capacity of dapagliflozin, effectively rescuing pioglitazone's pro-steatotic signaling.

01 Feb 2027·CHEMISTRY AND PHYSICS OF LIPIDS

From interfacial films to vesicles: Interactions of dapagliflozin with Tween 20-modified lipid membranes and their implications for encapsulation in transferosomes

Article

Author: Dopierała, Katarzyna ; Wilczewska, Katarzyna ; Kołodziejczak-Radzimska, Agnieszka ; Pawlikowski, Marcel

Understanding drug-lipid interactions is essential for the rational design of lipid-based nanocarriers. Dapagliflozin (DAPA), a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with expanding therapeutic applications, represents an attractive candidate for lipid-based delivery systems; however, the physicochemical basis of its interactions with lipid membranes remains insufficiently understood. In this study, Langmuir monolayers and lipid vesicles were employed as complementary systems to investigate DAPA-lipid interactions and their modulation by the edge activator Tween 20. Langmuir monolayer experiments demonstrated that DAPA markedly affected lipid packing, compressional properties, and relaxation behavior. Importantly, these effects depended on the presence of Tween 20, revealing a composition-dependent interplay between the drug, lipids, and edge activator rather than independent effects of the individual components. The interfacial studies also showed that the role of Tween 20 cannot be described solely in terms of monolayer fluidization. DAPA-loaded liposomes and Tween 20-containing transferosomes exhibited high apparent encapsulation efficiencies. DAPA markedly altered the particle-size distributions of both formulations, producing a multimodal distribution in liposomes and shifting the predominant intensity-weighted population of transferosomes toward the micrometer range. AFM measurements further demonstrated pronounced changes in vesicle nanomechanics, with both DAPA and Tween 20 reducing stiffness and Young's modulus relative to empty liposomes. Adhesion parameters increased when DAPA was encapsulated in the vesicles. Overall, the combined monolayer-vesicle approach reveals a composition-dependent interplay between DAPA, lipids, and Tween 20 that governs interfacial organization, particle-size distribution, and nanomechanical behavior. These findings highlight the importance of considering the drug as an active contributor to membrane properties rather than merely an encapsulated cargo and provide a physicochemical basis for further optimization of DAPA-containing transferosomal systems.

01 Feb 2027·TISSUE & CELL

Protective effects of dapagliflozin against methotrexate-induced liver injury: Involvement of Nrf2/HO-1 and NLRP3 inflammasome

Article

Author: Abdalrazaq, Nadeem Abdalsatar ; Kamel, Gellan Alaa Mohamed ; Mousah, Hamoudi Aliwi

Methotrexate (MTX) is a chemotherapeutic and immunosuppressive agent that can induce liver injury through oxidative stress and inflammatory mechanisms. Dapagliflozin (Dap), a selective SGLT2 inhibitor, exerts antioxidant and anti-inflammatory effects. This study investigated the protective effects of Dap against MTX-induced liver injury, with a focus on oxidative stress, Nrf2/HO-1 signaling, and NLRP3-related inflammatory responses. Twenty-four male albino rats were divided into four groups: control, MTX (20 mg/kg, single i.p. dose), MTX + Dap 5 mg/kg, and MTX + Dap 10 mg/kg, with Dap administered orally once daily for 10 days. MTX increased serum ALT and AST levels, elevated hepatic MDA, reduced GSH and SOD levels, and induced histopathological alterations. In addition, MTX decreased Nrf2 mRNA and HO-1 protein expression, while increasing NLRP3 mRNA, TNF-α, and IL-1β levels. Dap treatment improved liver enzyme profiles and histopathological features, enhanced antioxidant markers, upregulated Nrf2 mRNA and HO-1 protein expression, and downregulated NLRP3 mRNA and pro-inflammatory cytokine levels in a dose-dependent manner. Correlation analysis indicated that higher Nrf2 levels were associated with reduced oxidative stress and NLRP3-related gene expression. These findings suggest that Dap protects against MTX-induced liver injury by modulating antioxidant defenses and inflammatory signaling pathways.

402

News (Medical) associated with Dapagliflozin

30 Oct 2026

·www.fiercepharma.com

AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual savings by 2029. Savings from the “Reshaping for Sustainable Growth” program will be reinvested “principally in the pipeline,” AZ said Friday in its third-quarter earnings announcement. The company expects the three-year initiative to incur up to $2 billion in one-time restructuring costs. The overhaul follows similar cost-cutting initiatives launched by Big Pharma peers, including Pfizer, Bristol Myers Squibb, Merck & Co., Novo Nordisk and GSK, in recent years. AZ is refocusing its resources on pipeline growth following reports that a potential merger with BMS had fallen through . The reported combination, which would have created one of the world's largest pharmaceutical companies, faced investor pushback and raised questions about AZ's long-term growth outlook. Following the merger speculation, AZ CEO Pascal Soriot told Bloomberg that the British pharma does not need a major acquisition to sustain growth beyond 2030. During a press conference Friday, Soriot reaffirmed AZ's ambition to reach $80 billion in annual sales by 2030. “We believe we have the science, the pipeline and the team to deliver,” he said. While AZ is positioned to grow beyond 2030 without a major acquisition, Soriot said the company continues to look for opportunities to strengthen its portfolio. “We are constantly looking at, how do we strengthen our presence in a franchise or another, in a disease or another, and how do we add more value to our portfolio in a company?” he said. The restructuring is not expected to result in a net reduction in AZ's workforce, Chief Financial Officer Aradhana Sarin told reporters during the call. Although some positions will be eliminated, the company expects to create new roles as it reallocates resources. “It won’t lead to a net reduction in jobs,” Sarin said. “We are a growing company. We still have big ambitions. I’d say net-net, we’ll still be adding jobs, maybe different types of jobs or jobs in different areas.” “You don’t spend $1.5 billion without creating jobs,” Soriot said. “So right there, you see that there will be changes. It’s more reallocation of resources across the pipeline and across the world. In the end, we are still a growing company, and the idea is not to shrink the company. The opposite, actually.” The executives did not specify which job functions would be affected, but Soriot said the restructuring would involve reallocating roles and resources across geographic regions and business functions. Thanks to years of growth under Soriot's leadership, AZ was one of only three large pharmaceutical companies to consistently expand its workforce since 2021, a recent Fierce Pharma report shows. The company's last major restructuring initiative dates back to a separate $1.5 billion cost-cutting program launched in 2016, when its top-selling drug, Crestor, lost patent protection. The latest restructuring comes as AZ, like its Big Pharma peers, faces several near- and mid-term patent cliffs. Its blockbuster SGLT2 inhibitor Farxiga is already competing with generics in the U.S. and China, with global third-quarter sales falling 25% year over year to approximately $1.6 billion. Its antiplatelet drug Brilinta, PARP inhibitor Lynparza and respiratory medicine Symbicort have lost market exclusivity in certain markets. Meanwhile, the company faces additional patent expirations in the early 2030s for major oncology products, including the BTK inhibitor Calquence, EGFR-targeted lung cancer drug Tagrisso and PD-L1 inhibitor Imfinzi. Against that backdrop, Soriot highlighted 23 key clinical readouts expected in 2027 that collectively represent more than $20 billion in potential peak annual sales. These include multiple phase 3 readouts for Daiichi Sankyo-partnered antibody-drug conjugate Datroway and the oral selective estrogen receptor degrader Etcamah in adjuvant breast cancer. The two medicines are among 12 programs that Soriot said have non-risk-adjusted peak sales potential exceeding $5 billion. On the dealmaking front, AZ recently completed a $2 billion equity investment in Summit Therapeutics as part of a broader collaboration focused on combining AZ's antibody-drug conjugates with Summit's Akeso-partnered PD-1/VEGF bispecific antibody ivonescimab. “The logic behind this partnership is maximizing the value of our ADC platform,” Soriot said. “And of course, the logic for Summit is to maximize the value of ivonescimab by combining it with ADC. That will be an important part of cancer care in the future.” The Summit investment is one of several China-related deals struck by AZ, but potential regulatory changes in China and the U.S. could complicate future cross-border transactions. China is proposing new rules that would block foreign acquisitions of certain advanced biotechnologies involving cell and gene therapies and small interfering RNA, or siRNA. Meanwhile, the U.S. Treasury Department has proposed expanding restrictions under the COINS Act to include certain pharmaceutical investments in China, which could prohibit some U.S. outbound investments in the country's biotech sector. Soriot said AZ is closely monitoring the proposed regulatory changes and would comply with any new rules that take effect. “But it’s important to remember that in science, collaboration is important, and in cancer or other diseases, people will want access to medicines that can save their lives,” he said. If AZ licenses a product from China and commercializes and manufactures it in the U.S., Soriot said, the drug “becomes a U.S. product, saving U.S. lives.”

Acquisition

16 Oct 2026

·www.fiercepharma.com

Lilly's obesity pill, RevMed's pancreatic cancer breakthrough among slew of CHMP endorsements in Europe

Across the pond, European regulators handed down a pair of pivotal approval recommendations this week, making way for a new front in Novo and Eli Lilly’s oral GLP-1 showdown and endorsing Revolution Medicines’ potential pancreatic cancer game changer, which has received some investor scrutiny of late following the recent release of FDA review documents in the U.S. Both decisions—which cover Lilly’s oral GLP-1 treatment Foundayo and RevMed’s RAS inhibitor Rasonque—came by way of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which has recommended six new drugs for approval and jockeyed for five label extensions in its latest wave of regulatory action. CHMP’s approval recommendations are not the end of the road for a drug application in the European Union, with the decisions still subject to final sign-off by the European Commission. However, formal approval often follows the human medicines committees’ blessing. The marketing recommendation for Lilly’s Foundayo, which leverages the orally delivered GLP-1 molecule orforglipron, addresses both obesity and Type 2 diabetes for adults, coming on the heels of the weight management-only EU endorsement that Novo received for its rival Wegovy pill back in May. Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine still carries in Europe. Novo retired the Rybelsus brand in the U.S. and relaunched a slight reformulation of oral semaglutide in Type 2 diabetes under the Ozempic pill moniker earlier this year. The new EU endorsement for Foundayo, meanwhile, applies to treatment of obesity or overweight in adults with at least one weight-related health problem. In diabetes, Foundayo can either be taken alone when metformin isn’t a good fit for patients, or together with other diabetes meds, the CHMP explained in a Friday release. The CHMP based its obesity green light on a pair of studies that found patients on Foundayo lost around 5% to 11% of their body weight after 72 weeks, dependent upon the exact dose received, versus a range of 2% to 2.5% on placebo. And in the four primary studies of Foundayo in Type 2 diabetes, Lilly’s GLP-1 tablet was linked to A1C reductions of around 1.2 to 1.9 percentage points—again dose-dependent—compared to a 0.4-to-0.8 percentage-point decline on placebo. Lilly also pitted its pill against AstraZeneca’s SGLT2 inhibitor Farxiga and Novo’s oral semaglutide at the 7- and 14-mg doses in Type 2 diabetes, coming out on top in those comparisons as well. Aside from the likely pent-up patient demand for another oral weight loss option in the EU, investors and industry watchers will be closely monitoring Foundayo’s performance in the transatlantic market. After gaining a notable market advantage over Novo’s bread-and-butter obesity injectable Wegovy with its own Zepbound in recent years, Lilly has struggled to gain a lead after launching second to Novo in the oral obesity drug space earlier this year. The other banner endorsement from the CHMP this week came for RevMed’s Rasonque as a second-line monotherapy in patients with metastatic pancreatic adenocarcinoma, rounding out a similar green light from the FDA in late August. Should Rasonque snare the European Commission’s blessing, it will become the first broad RAS-targeted treatment for this specific patient population in the EU, RevMed said in an Oct. 15 release. As in the case of the recent U.S. nod, RevMed leaned on its landmark RASolute 302 trial to support its approval ambitions in Europe. RevMed reported that Rasonque had doubled overall survival in the phase 3 study back in April and then revealed at ASCO that the RAS inhibitor had doubled progression-free survival , too, prompting a standing ovation from the conference’s sizeable audience. “Today’s positive CHMP opinion marks a major step toward making Rasonque available to eligible adults with metastatic pancreatic cancer in the European Union,” Mark Goldsmith, M.D., Ph.D., RevMed’s CEO, said in a statement. As major hopes ride on Rasonque, the drug faced some unexpected investor unease earlier this month with the release of FDA review documents, which led to questions about the drug’s positioning in a key KRAS subgroup. The shareholder jitters, which pressured RevMed’s stock last week, largely revolved around the medicine’s lower posted objective response rate in patients with KRAS G12D mutations, which represent the most common subtype of KRAS mutations in pancreatic cancer. Still, multiple analyst shops flagged the stock movement as an overreaction, with the team at Leerink Partners noting last week that the subgroup analysis “doesn’t change anything for Rasonque.” In a statement to Fierce, a RevMed representative stressed that overall survival remains “the gold standard endpoint in oncology and is what matters most to patients and physicians, particularly in pancreatic cancer.” Moreover, the analysts pointed to apparent other benefits in Rasonque despite lower ORR numbers in G12D and another subgroup of patients. Beyond Rasonque and Foundayo, other drugs to win favor with CHMP this week included Ascendis’ Yuviwel for pediatric achondroplasia and Orphelia Pharma’s glioblastoma multiforme and malignant glioma med Kizfizo, which has orphan drug status in the U.S.—plus endorsements for two separate biosimilar referencing Roche’s Lucentis (ranibizumab) and the neutropenia med filgrastim. The regulatory body also put its weight behind label extensions for AstraZeneca’s avian influenza vaccine, as well as Novo’s insulin icodec-semaglutide combo for Type 2 diabetes, Kyinsu, plus Johnson & Johnson’s Talvey, Ionis’ Tryngolza and Pfizer’s Tukysa.

Phase 3Clinical ResultDrug ApprovalOrphan Drug

14 Oct 2026

·www.eccogene.com

Eccogene Announces First Patient Enrolled in China in Global Phase III Clinical Program for Elecoglipron

Eccogene, a global clinical-stage biotechnology company developing therapies for cardiometabolic diseases and inflammatory disorders, today announced that the first patient has been enrolled in China in the global Phase III clinical program for elecoglipron (AZD5004/ECC5004). Elecoglipron is an investigational, once-daily, oral small molecule GLP-1 receptor agonist for the treatment of cardiometabolic diseases. The extensive elecoglipron Phase 3 program includes the Embold Phase III trials which will evaluate elecoglipron as treatment for people with obesity or overweight, with and without type 2 diabetes. The Eluminate Phase III trials will evaluate elecoglipron, as monotherapy and in combination with dapagliflozin, as treatment for people with type 2 diabetes. Two additional indication-seeking outcome trials (Elevate) will evaluate elecoglipron as treatment for people with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF), and chronic kidney disease (CKD), on the background of dapagliflozin plus other standard of care therapies. Eccogene is working closely with its partner AstraZeneca to advance the Phase III clinical development of elecoglipron in Greater China. Clinical trial sites across Greater China will participate in the global Phase III program, enabling patients in the region to participate in these pivotal registration and outcomes studies alongside patients globally. Jingye Zhou, Ph.D., Chief Executive Officer of Eccogene, said: “The first patient enrollment in China marks an important milestone in the global Phase III clinical program for elecoglipron, expanding its evaluation across a broader and more diverse patient population. This milestone brings us one step closer to providing a more convenient and innovative treatment option for patients in China living with obesity/overweight, type 2 diabetes, heart failure and CKD. We will continue to work closely with AstraZeneca to advance the clinical development of elecoglipron in Greater China with high quality and efficiency, and contribute to the global evidence base for elecoglipron across cardiometabolic diseases.” Elecoglipron has the potential to become an important oral therapy for cardiometabolic diseases, both as a monotherapy in population with obesity or overweight with comorbidities, and type 2 diabetes, as well as in combination with other small-molecule therapies (such as dapagliflozin), enabling tailored treatment approaches that address different disease mechanisms and comorbidity profiles. As an oral small molecule, elecoglipron offers inherent advantages in large-scale manufacturing and supply chain management compared with peptide-based or injectable therapies. With no food or fasting restrictions, elecoglipron also has the potential to improve long-term treatment adherence and facilitate broader adoption in primary care chronic disease management, ultimately expanding treatment options for a wider population of patients with cardiometabolic diseases. Leveraging its translational research workflow and deep understanding of metabolic disease pathways, Eccogene is advancing a pipeline of next-generation therapeutics that can be used alone or in combination with GLP-1 receptor agonists. In addition to elecoglipron, the Company’s pipeline includes clinical-stage programs targeting THR-β and SSAO, as well as preclinical programs targeting GIPR, AmylinR, and others. About Elecoglipron Elecoglipron is an investigational oral, small-molecule GLP-1 receptor agonist discovered by Eccogene. It is designed to offer a convenient once-daily dosing regimen with no food- or water-related restrictions, which may help support patient adherence and broaden access. In November 2023, Eccogene entered into an exclusive licensing agreement with AstraZeneca for elecoglipron outside Greater China, while retaining co-development and co-commercialization rights within Greater China. Elecoglipron is currently being evaluated in an extensive global Phase III clinical program spanning multiple indications, including weight management, type 2 diabetes, heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), and chronic kidney disease (CKD). About Eccogene Eccogene is a global clinical-stage biotechnology company established in 2018 with an integrated pipeline comprising three clinical-stage drug candidates and multiple preclinical programs. The company aims to become a global leader in developing therapies for cardiometabolic diseases and inflammatory disorders. For more information, please visit www.eccogene.com or follow the company on LinkedIn. Contacts investors@eccogene.com Forward-Looking Statements This press release may contain forward-looking statements that reflect the Company’s current expectations, beliefs, plans and projections. These statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those anticipated. Such factors include, without limitation, changes in market conditions, regulatory developments, competitive landscape and general economic conditions. Save as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Phase 3License out/in

100 Deals associated with Dapagliflozin

External Link

KEGG	Wiki	ATC	Drug Bank
D09763	Dapagliflozin	A10BK01	DB06292

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Japan	AstraZeneca Pharmaceuticals Co. Ltd.	26 Mar 2019
Chronic heart failure	European Union	AstraZeneca AB	11 Nov 2012
Chronic heart failure	Iceland	AstraZeneca AB	11 Nov 2012
Chronic heart failure	Liechtenstein	AstraZeneca AB	11 Nov 2012
Chronic heart failure	Norway	AstraZeneca AB	11 Nov 2012
Chronic Kidney Diseases	Australia	AstraZeneca Pty Ltd.	22 Oct 2012
Diabetes Mellitus, Type 2	Australia	AstraZeneca Pty Ltd.	22 Oct 2012
Heart Failure	Australia	AstraZeneca Pty Ltd.	22 Oct 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute myocardial infarction	Phase 3	Sweden	AstraZeneca PLC	22 Dec 2020
Acute myocardial infarction	Phase 3	United Kingdom	AstraZeneca PLC	22 Dec 2020
Acute Q wave myocardial infarction	Phase 3	Sweden	AstraZeneca PLC	22 Dec 2020
Acute Q wave myocardial infarction	Phase 3	United Kingdom	AstraZeneca PLC	22 Dec 2020
Acute decompensated heart failure	Phase 3	United States	AstraZeneca PLC	01 Apr 2020
Dyspnea, Paroxysmal	Phase 3	United States	AstraZeneca PLC	01 Apr 2020
Heart failure with reduced ejection fraction	Phase 3	United States	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	Japan	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	Brazil	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	Canada	AstraZeneca PLC	09 Apr 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06888505 (DAPA-AIC, Pubmed \| Future Sci OA)	Phase 2	-	94	Dapagliflozin 10 mg	vwdpgyluhm(eipajarznv) = gepvvxbyet cydtgfwxza (dbmdhmmyyj )	Positive	31 Dec 2026
				Placebo	vwdpgyluhm(eipajarznv) = ryeesyaarf cydtgfwxza (dbmdhmmyyj, 3.27)
ACR2026	Not Applicable	Lupus Nephritis	17	Dapagliflozin	jcoohxemoc(fmeeqlmooq) = dmzilbbgoi hlshacazbe (qmfslmyslu ) View more	Positive	06 Nov 2026
AASLD2026	Not Applicable	Liver Cirrhosis \| Ascites	73	Dapagliflozin plus standard medical therapy	ueqyhgrpcn(vscezvflvs) = monqsmhuka ignrldnmww (rmblmrgpos ) View more	Positive	05 Nov 2026
				Standard medical therapy alone	ueqyhgrpcn(vscezvflvs) = ysdxlogzmd ignrldnmww (rmblmrgpos ) View more
NCT02383238 \| NCT02471963 (Pubmed \| Endocrinol Diabetes Metab)	Phase 3	Diabetes Mellitus, Type 2	123	Empagliflozin	chdzkckhtu(aqieswzhdj) = dcmaiguksh zzrccezjnk (knfpqbigup ) View more	Positive	01 Nov 2026
				Dapagliflozin	ijbxcgolzt(wyjftrphld) = jiojxfmqme uzpvhgdnga (nvvrzoctju ) View more
NCT03269058 (Pubmed \| Diabetologia)	Phase 2	Diabetes Mellitus, Type 2	24	Dapagliflozin 10 mg/day	apvdoukdal(fjayqulaoa) = those who received dapagliflozin (n=17) showed a significant reduction of HbA1c (p=0.001) vrdvftgnmg (yfuqnvtipf ) View more	Positive	01 Nov 2026
				Placebo
NCT06268873 (BaxDuo-Arctic, ASN2026)	Phase 3	Renal Failure, Progressive, With Hypertension	2,534	Baxdrostat 1 mg/Dapagliflozin 10 mg	bhzsldkpbh(nxrrozutqq) = frenxjstma tlevvlgbrj (ydhhjaiqli, 15.7) View more	Positive	23 Oct 2026
ASN2026	Not Applicable	Renal transplant rejection	254	Dapagliflozin	tqgzsnndfz(ekzpywtkgx) = Occurrence of diabetic ketoacidosis was 0.8%, acute kidney injury was 5.1%, urinary infections was 15.0% with male gender (adjusted odds ratio 0.30, 95% CI 0.14-0.63, p=0.001) protective against UTI, hyperkalemia was 11.4%, hypoglycemia was 5.9%, and lower limb ulceration was 2%. czayepiifh (wzasqjnael ) View more	Positive	23 Oct 2026
ASN2026	Not Applicable	Idiopathic Membranous Glomerulonephritis	156	RASi plus dapagliflozin	nvtkjfdion(hewswfmuub): P-Value = 0.045 View more	Positive	23 Oct 2026
				RASi monotherapy
NCT05884866 (DapaBalci-Leap, ASN2026)	Phase 2	Chronic Kidney Diseases	99	10 mg Dapagliflozin	mkrunfnccd(bnvocmzati) = wgfcxjvevy kianwdsiit (baykgjehsr, 0.17 - 0.83)	Positive	22 Oct 2026
				150 mg Balcinrenone	khixtzqzzc(dstogeaosq) = prwykoxyni hjrznealiy (jxwzlpnnno )
NCT04717986 (Pubmed \| Curr Probl Cardiol)	Phase 3	-	181	Dapagliflozin 10 mg	urlvpsrhci(xbylfgyekw) = ujfwbjjyco xkfvjoklqk (evtrqumezv ) View more	Positive	01 Oct 2026
				Placebo	jeyjfnhmvn(yrbhoskoes) = tomxkbellb guzpxzxyyv (nkveenarmp )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis